Italian Network for Tumor Biotherapy   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Italy (2014)

Organization Overview

First Clinical Trial
2014
NCT01654692
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Italian Network for Tumor Biotherapy Foundation

Active Ingredients

Drugs in Phase 3 Trials (3)

fotemustine (2 trials)

ipilimumab (yervoy) (4 trials)

nivolumab (opdivo) (2 trials)

Drugs in Phase 2 Trials (3)

durvalumab (imfinzi) (1 trial)

guadecitabine (2 trials)

tremelimumab (Imjudo) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Neoplasms (Phase 3)

Melanoma (Phase 3)

Mesothelioma (Phase 2)

Neoplasm Metastasis (Phase 3)

Neoplasms, Second Primary (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 6